Bortezomib, thalidomide, and dexamethasone with or without daratumumab for transplantation-eligible patients with newly diagnosed multiple myeloma (CASSIOPEIA): health-related quality of life outcomes of a randomised, open-label, phase 3 trial

Publication date: December 2020Source: The Lancet Haematology, Volume 7, Issue 12Author(s): Murielle Roussel, Philippe Moreau, Benjamin Hebraud, Kamel Laribi, Arnaud Jaccard, Mamoun Dib, Borhane Slama, Véronique Dorvaux, Bruno Royer, Laurent Frenzel, Sonja Zweegman, Saskia K Klein, Annemiek Broijl, Kon-Siong Jie, Jianping Wang, Veronique Vanquickelberghe, Carla de Boer, Tobias Kampfenkel, Katharine S Gries, John Fastenau
Source: The Lancet Haematology - Category: Hematology Source Type: research